# CancerNetwork

> CancerNetwork - Healthcare Publication

- Base URL: https://www.cancernetwork.com
- Generated: 2026-07-20T13:24:39.510Z
- Content updates: multiple times daily

## Content Access for AI Agents

This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML.

**Supported content types:**
- `text/markdown` — Clean Markdown with YAML frontmatter
- `text/plain` — Plain text (same as Markdown)
- `text/html` — Default HTML response

**Example request:**
```
curl -H "Accept: text/markdown" https://www.cancernetwork.com/view/article-slug
```

**YAML frontmatter schema** (returned with every Markdown response):

| Field | Type | Description |
|-------|------|-------------|
| `title` | string | Article headline |
| `description` | string | Summary/excerpt (max 300 chars) |
| `url` | string | Canonical article URL |
| `canonical_url` | string | Canonical URL if different from `url` |
| `published` | ISO 8601 | Original publication date |
| `modified` | ISO 8601 | Last modification date |
| `authors` | string[] | Author display names |
| `content_type` | string | Content category (e.g., "News", "Clinical") |
| `categories` | string[] | Taxonomy categories |
| `tags` | string[] | SEO tags |
| `image` | string | Featured image URL |
| `publisher` | string | Publication/site name |

**Discovery headers** (included on all responses):
- `Link: <https://www.cancernetwork.com/llms.txt>; rel="llms"` — RFC 8288 link to this file
- `X-Llms-Txt: https://www.cancernetwork.com/llms.txt` — Explicit discovery header

## Usage Policy

- Robots policy: [https://www.cancernetwork.com/robots.txt](https://www.cancernetwork.com/robots.txt)
- Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329)
- Rate guidance: prefer RSS and sitemap feeds over crawling individual pages
- Attribution: All content © MJH Life Sciences. Include source URLs when citing.

## Content Categories

- [Around the Practice](https://www.cancernetwork.com/around-the-practice)
- [Between the Lines](https://www.cancernetwork.com/between-the-lines)
- [Breaking Barriers](https://www.cancernetwork.com/breaking-barriers)
- [Clinical](https://www.cancernetwork.com/clinical)
- [Clinical Consult](https://www.cancernetwork.com/clinical-consult)
- [Conference](https://www.cancernetwork.com/conference)
- [Face-Off](https://www.cancernetwork.com/face-off)
- [From All Angles](https://www.cancernetwork.com/from-all-angles)
- [Frontline Forum](https://www.cancernetwork.com/frontline-forum)
- [Global Bulletin](https://www.cancernetwork.com/global-bulletin)
- [Hero](https://www.cancernetwork.com/hero)
- [Integrative Care](https://www.cancernetwork.com/integrative-care)
- [Media](https://www.cancernetwork.com/media)
- [Meeting of the Minds](https://www.cancernetwork.com/meeting-of-the-minds)
- [Men's Health](https://www.cancernetwork.com/mens-health)
- [News](https://www.cancernetwork.com/news)
- [OncView](https://www.cancernetwork.com/k-cast)
- [Podcasts](https://www.cancernetwork.com/podcasts)
- [Publications](https://www.cancernetwork.com/journals)
- [Quizzes](https://www.cancernetwork.com/resources/quizzes)
- [Readout 360](https://www.cancernetwork.com/readout-360)
- [Resources](https://www.cancernetwork.com/resources)
- [Roles](https://www.cancernetwork.com/roles)
- [The Bispecifics Network](https://www.cancernetwork.com/the-bispecific-network)
- [Training Academy](https://www.cancernetwork.com/training-academy)
- [Treatment Algorithms with the Oncology Brothers](https://www.cancernetwork.com/treatment-algorithms-with-the-oncology-brothers)
- [Tumor Board Series](https://www.cancernetwork.com/tumor-board-series)
- [Video Series](https://www.cancernetwork.com/video-series)
- [Videos](https://www.cancernetwork.com/videos)
- [Webinars](https://www.cancernetwork.com/webinars)
- [Year in Review](https://www.cancernetwork.com/year-in-review)

## Featured Content

- [Managing Safety and Infection Risk With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma](https://www.cancernetwork.com/view/managing-safety-and-infection-risk-with-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma): Dr. Binod Dhakal, Dr. Prerna Mewawalla, and Dr. Carol Ann Huff discuss practical strategies for managing the safety profile of BCMA-directed bispecifi...
- [Future Directions and Key Takeaways in the Field of cSCC](https://www.cancernetwork.com/view/future-directions-and-key-takeaways-in-the-field-of-cscc): Explore new cutaneous SCC strategies: neoadjuvant PD-1, combo regimens, intralesional RP1, and early multidisciplinary referral.
- [Clinical Scenarios: Matching Regimen to Patient Profile](https://www.cancernetwork.com/view/clinical-scenarios-matching-regimen-to-patient-profile): Two clinical scenarios illustrated shared decision-making in practice: a 58-year-old woman with TP53 mutation, L858R, and asymptomatic brain metastase...
- [Immunocompromised Patients with CSCC, Future Directions, and Closing Pearls](https://www.cancernetwork.com/view/immunocompromised-patients-with-cscc-future-directions-and-closing-pearls): NP Schollenberger addresses the particularly challenging and understudied population of immunocompromised patients with advanced CSCC.
- [Biomarkers and Immunocompromised Patients](https://www.cancernetwork.com/view/biomarkers-and-immunocompromised-patients): Explores why PD-L1 falls short in skin SCC and how TMB and transplant-safe immunotherapy may shape personalized care.
- [Multidisciplinary Coordination, Biomarkers, and Immunocompromised Patients with CSCC](https://www.cancernetwork.com/view/multidisciplinary-coordination-biomarkers-and-immunocompromised-patients-with-cscc): Both panelists describe multidisciplinary care coordination models.
- [Resistance Biology: MARIPOSA vs. FLAURA2 Reshaping Debate](https://www.cancernetwork.com/view/resistance-biology-mariposa-vs-flaura2-reshaping-debate): The debate examined whether amivantamab-lazertinib or osimertinib-chemotherapy more favorably reshapes resistance biology, with the MARIPOSA team citi...
- [Applying MajesTEC Data Across Patient Populations in Relapsed/Refractory Multiple Myeloma](https://www.cancernetwork.com/view/applying-majestec-data-across-patient-populations-in-relapsed-refractory-multiple-myeloma): Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss how differences in patient populations across the MajesTEC clinical program may...
- [How Will Orca-T Impact the Hematologic Oncology Paradigm?](https://www.cancernetwork.com/view/how-will-orca-t-impact-the-hematologic-oncology-paradigm-): The approval of Orca-T represents a “big advance” that must be studied further, according to Wendy Stock, MD.
- [Key Clinical Takeaways in Newly Diagnosed Multiple Myeloma](https://www.cancernetwork.com/view/key-clinical-takeaways-in-newly-diagnosed-multiple-myeloma): Dr. Ajai Chari and NP Samantha Shenoy conclude the program by summarizing the key clinical insights surrounding the management of newly diagnosed mul...

## Feeds and Indexes

- [RSS Feed](https://www.cancernetwork.com/rss.xml): Latest articles in XML syndication format
- [Sitemap](https://www.cancernetwork.com/sitemap.xml): Complete URL index for all published pages
- [News Sitemap](https://www.cancernetwork.com/sitemap-news.xml): Recent articles optimized for news indexing
- [Authors Directory](https://www.cancernetwork.com/authors): Browse all contributors and their published work